logo
  

Pfizer, BioNTech Initiate BLA Process With FDA For The COVID-19 MRNA Vaccine - Quick Facts

Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced Friday that they have initiated the Biologics License Application (BLA) process with the U.S. Food and Drug Administration (FDA) for approval of their mRNA vaccine to prevent COVID-19 in individuals 16 years of age and older.

The companies initiated the BLA by submitting the nonclinical and clinical data needed to support licensure of the COVID-19 vaccine. The data to support the BLA will be submitted by the companies to the FDA on a rolling basis over the coming weeks, with a request for Priority Review. The BLA approval will be based on the pivotal Phase 3 trial and longer-term follow-up data.

The Prescription Drug User Fee Act (PDUFA) goal date for a decision by the FDA will be set once the BLA is complete and formally accepted for review by the agency.

Pfizer and BioNTech also have submitted an application to expand the current Emergency Use Authorization (EUA) for their COVID-19 vaccine to include individuals 12 to 15 years of age. The companies intend to submit a supplemental BLA to support licensure of the vaccine in this age group later.

The Pfizer-BioNTech COVID-19 Vaccine is currently available in the U.S. under an EUA granted by the FDA on December 11, 2020. Since then, the companies have delivered more than 170 million doses of the vaccine across the U.S.

The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the FDA, but has been authorized for emergency use by FDA under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 16 years of age and older.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
PepsiCo, Inc. (PEP) has reached an agreement with private equity firm PAI Partners to sell Tropicana, Naked and other select juice brands across North America. The agreement also includes an irrevocable option to sell certain juice businesses in Europe. The combined pre-tax cash proceeds will be approximately... Drug major Eli Lilly And Co. reported Tuesday weak profit in its second quarter, despite higher revenues driven by strong volume across core business and most major geographies. Further, the company trimmed its forecast for fiscal 2021 earnings on a reported basis and margin, while maintained adjusted earnings view above market estimates. The company also tightened full-year revenue forecast. Shares of BMW Group were losing around 5 percent in German trading after the luxury automaker warned Tuesday that its second half-year is likely to be more volatile, affected by supply bottlenecks, high prices for raw materials and a shortage of semiconductors. This was despite reporting strong second-quarter results driven by solid demand.
Follow RTT